Skip to content

Chris Serrand

3 papers in the library · 26 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Journal of Affective Disorders January 19, 2026 Maria Garcia Garcia, Dahbia Belahda, Carine Graux et al.

Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction July 24, 2025 Amandine Luquiens, Dahbia Belahda, Carine Graux et al. 22 citations

Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted psychotherapy for patients with comorbid...

Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis.

Journal of Eating Disorders March 17, 2025 Paula J Escobedo-Aedo, Chris Serrand, Sarah Kabani et al. 4 citations

Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic in depression and suicidal ideations, could be an innovative adjuvant treatment for the AN spectrum. We describe a case series...